Headlines Covid-19 Specialties Trending Feeds Videos

PURPOSE Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which...

PURPOSE Among patients receiving chemotherapy, symptom monitoring with electronic patient-reported outcomes (ePROs) is associated with improved clinical outcomes, satisfaction, and compliance with therapy. Standard...

AuthorsKyle T. EnriquezVanderbilt University Medical Center, Nashville, TNKyle T. Enriquez, Gowri Satyanarayana, Maheen Abidi, Shailesh M Advani, Pamela Egan, Arielle Elkrief, Benjamin French, Christopher...

The FDA has granted an orphan drug designation to gunagratinib as a potential therapeutic option for patients with...

A new biosignature tool helps with treatment decisions after lumpectomy for ductal carcinoma in situ (DCIS), eg, by identifying those who can skip...

Mashup Score:2

LWW Journals

metabolic - 28 mins

Mashup Score:2

Metabolic Inhibitor Shows Antitumor Effects in Ovarian PatientsThe glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center’s...

Read it now on...

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Bijal D. Shah, Moffitt Cancer Center, Tampa, US. We asked, Is there positive...

Mashup Score:1

LWW Journals

CLL - 1 day

Mashup Score:1

RESONATE-2 Study Show Survival Benefits in Previously Untreated CLL PatientsBy Warren FroelichIn a 7-year follow-up, older patients with chronic lymphocytic leukemia (CLL) who received...

A new biosignature tool helps with treatment decisions after lumpectomy for ductal carcinoma in situ (DCIS), eg, by identifying those who can skip...